News
I celebrated five years since my bone marrow transplant with a surprise video from my donor, a beautiful reminder of the life ...
18h
TipRanks on MSNMoleculin Biotech Gains Approval for Phase 2B/3 AML StudyAn announcement from Moleculin Biotech ( ($MBRX) ) is now available. On July 9, 2025, Moleculin Biotech announced that the Regulation Agency for ...
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Insider Monkey on MSN1d
Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AMLThe sNDA seeks approval for the treatment of relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia/AML. The ...
After a leukemia diagnosis, a Rome family found support at an Atlanta Ronald McDonald House while their son underwent chemotherapy at Children’s Healthcare of Atlanta.
Syndax now has two approved therapies, but the share price remains under pressure despite these milestones. See why SNDX ...
June marks AML Awareness Month. It is a time to understand acute myeloid leukaemia. AML is a blood cancer needing quick ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results